Saturday 17 October 2026
Export RVPH’s income statement to Excel — free account
Reviva Pharmaceuticals Holdings, Inc.
RVPH Healthcare Biotechnology
In the quarter to June 2026, EPS grew 92.1% and free cash flow grew 57.8%, each against the same quarter a year earlier.
0.45
0.03
−6.25%
Follow RVPH
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 193.00 | 196.00 | 146.20 | 52.20 | 10.60 | 70.00 | 12.00 | 5.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | 210.00 | 211.20 | 302.00 | 192.20 | 122.00 | 185.00 | 113.40 | 43.40 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 4 | 5 | 5 | 10 | 15 | 14 | 14 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | — | — | — | — | — | |||||
| EBT | — | — | 1 | (1) | (4) | (9) | (28) | (39) | (30) | (20) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | 0 | (1) | (4) | (9) | (28) | (39) | (30) | (20) | |||||
| Depreciation | — | 0 | 0 | 0 | 0 | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | 1.39 | (6.12) | (24.80) | (11.60) | (25.00) | (33.00) | (18.00) | (5.48) | |||||
| Cash flow | — | 0.00 | (0.32) | (1.58) | (26.56) | (14.42) | (19.43) | (23.80) | (19.88) | (6.78) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | 0.00 | (0.32) | (1.58) | (26.56) | (14.42) | (19.43) | (23.80) | (19.88) | (6.78) | |||||
| Book value | — | 0.00 | 12.10 | (49.22) | 35.70 | 38.79 | 8.60 | 4.81 | 0.48 | 2.38 | |||||
| Shares, m | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | 0 | 0 | (4) | (11) | (19) | (28) | (34) | (25) | ||||
| Capex | — | 0 | 0 | — | — | — | — | — | — | — | |||||
| Free cash flow | — | 0 | 0 | 0 | (4) | (11) | (19) | (28) | (34) | (25) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | 0 | (7) | 7 | 29 | 9 | 7 | 0 | 8 | ||||
| Total debt | — | — | — | 4 | 1 | — | — | — | — | — | |||||
| Net debt | — | 0 | 0 | 4 | (9) | (30) | (19) | (23) | (13) | (14) | |||||
| Shareholders’ equity | — | 5 | 5 | (7) | 5 | 29 | 8 | 6 | 1 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | 0.00 | 0.88 | (2.58) | (10.84) | (42.43) | (112.31) | (184.22) | (152.63) | (126.42) | ||||
| ROIC | — | 0.00 | (2.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 0.00 | 11.15 | 5.48 | (72.30) | (49.91) | (152.43) | (556.38) | (916.17) | (419.97) | |||||
Negative figures in brackets.
Charts ten years each
Reviva Pharmaceuticals Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BGMS Bio Green Med Solution, Inc. | $5.5M | — (loss-making) | — (loss-making) | +3,260.00% (above 0%: growing) | n/m | +66.67% (above 0%: growing) | 23.51% | (124.40%) | Compare |
| CELZ Creative Medical Technology Holdings, Inc. | $5.4M | — (loss-making) | — (loss-making) | 0.00% | n/m | −27.05% (below 0%: shrinking) | 66.67% | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.2M | — (loss-making) | — (loss-making) | −28.00% (below 0%: shrinking) | n/m | +15.58% (above 0%: growing) | 100.00% | (27,742.59%) | Compare |
| PULM Pulmatrix, Inc. | $5.2M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | |
| LGVN Longeveron Inc. | $4.8M | — (loss-making) | — (loss-making) | −9.18% (below 0%: shrinking) | n/m | −49.12% (below 0%: shrinking) | 63.41% | (2,150.17%) | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.7M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| PCSA Heatwurx Inc. | $4.7M | 1.6× | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| DRMA Dermata Therapeutics, Inc. | $4.5M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $5.0M | — | — | −9.18% | — | +12.79% | 65.04% | (62.20%) |
Reviva Pharmaceuticals Holdings, Inc. (RVPH) key facts
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a Biotechnology company in the Healthcare sector.
- As of October 16, 2026, RVPH traded at $0.45, a market capitalization of $5.0 million.
- Return on equity was −420.0% and debt-to-equity 0.00.